Gramza, Ann W.

Harpoon Therapeutics, Inc., South San Francisco, CA

1 paper on CoChat

Most cited papers

Verified
Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).
Beltran, H., Dowlati, A., Jain, P., Johnson, M. L., Sanborn, R. E., Thompson, J. R., Mamdani, H., Schenk, E. L., Aggarwal, R. R., Sankar, K., et al. (2024) · Journal of Clinical Oncology
Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers
Cited by 32

Go further with a free account

Verify every reference, keep papers in a library, and ask questions across them.

Sign up - it is free